A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy Participants

Completed · Phase 1 · Has a placebo group

Conditions studied: APOL1-mediated Kidney Disease

In brief

The purpose of this study is to evaluate the safety, tolerability, and PK of single and multiple ascending doses of VX-840 in healthy participants.

Key facts

Study ID
NCT05324410
Run by
Vertex Pharmaceuticals Incorporated
People needed
88
Starts
2022-04-07
Expected to finish
2022-11-07
Last updated by the study team
2022-12-08

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.